Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAP07 trial in locally advanced pancreatic adenocarcinoma
ACTRN12609000158268Phase 3Completed
- Sponsor
- Australasian Gastro-Intestinal Trials Group
- Start
- Jul 2010
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of gemcitabine, erlotinib and capecitabine in pancreatic adenocarcinoma (PDAC) (4 arms), sponsored by Australasian Gastro-Intestinal Trials Group. Primary endpoint: Overall survival comparison of chemoradiotherapy versus continued chemotherapy after induction. Started Jul 2010; status: completed.
02
Drugs
gemcitabineerlotinibcapecitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ACTRN12609000158268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000158268.